Frank Mottola - 02 Nov 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Reporting relationship
SVP, Chief Tech. Ops. Officer
Issuer ticker
SUPN
Reported as of
02 Nov 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
04 Nov 2026, 16:27:59 UTC
Prior SEC filing
02 Nov 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Timothy C. Dec, as attorney-in-fact
Filing notes and source

Key filing fact

Frank Mottola filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 04 Nov 2026.

Key facts

  • This page summarizes Frank Mottola's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
  • 17 reported transactions and 16 derivative rows are listed below.
  • Accepted by SEC: 04 Nov 2026, 16:27.

Change

  • Previous filing in this sequence was filed on 02 Nov 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001804567 Primary reporting owner

Mottola Frank

Relationship
SVP, Chief Tech. Ops. Officer
Address
C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Signature date
04 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SUPN transaction

Common Stock

Other

Transaction value
Shares
-19,544
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SUPN transaction Derivative

Restricted Stock Unit

Other

Transaction value
Shares
-100,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
100,000
Exercise price
$0.000000
Footnotes
F2, F3
SUPN transaction Derivative

Performance Share Unit

Other

Transaction value
Shares
-3,500
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,500
Exercise price
$0.000000
Footnotes
F2, F4, F5
SUPN transaction Derivative

Performance Share Unit

Other

Transaction value
Shares
-3,350
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,350
Exercise price
Footnotes
F2, F4, F6
SUPN transaction Derivative

Performance Share Unit

Other

Transaction value
Shares
-3,750
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,750
Exercise price
Footnotes
F2, F4, F7
SUPN transaction Derivative

Restricted Stock Unit

Other

Transaction value
Shares
-1,875
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,875
Exercise price
Footnotes
F2, F8, F9
SUPN transaction Derivative

Restricted Stock Unit

Other

Transaction value
Shares
-2,500
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,500
Exercise price
Footnotes
F2, F8, F10
SUPN transaction Derivative

Restricted Stock Unit

Other

Transaction value
Shares
-3,375
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,375
Exercise price
Footnotes
F2, F8, F11
SUPN transaction Derivative

Restricted Stock Unit

Other

Transaction value
Shares
-3,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,000
Exercise price
Footnotes
F2, F8, F12
SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
Shares
-14,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
14,000
Exercise price
$36.75
Footnotes
F2, F13
SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
Shares
-22,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
22,000
Exercise price
$23.99
Footnotes
F2, F14
SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
Shares
-17,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
17,000
Exercise price
$29.61
Footnotes
F2, F15
SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
Shares
-18,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
18,000
Exercise price
$32.20
Footnotes
F2, F16
SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
Shares
-30,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
30,000
Exercise price
$38.60
Footnotes
F2, F17
SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
Shares
-25,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
25,000
Exercise price
$27.94
Footnotes
F2, F18
SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
Shares
-20,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
20,000
Exercise price
$33.52
Footnotes
F2, F19
SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
Shares
-13,500
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
13,500
Exercise price
$50.20
Footnotes
F2, F20
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Frank Mottola is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 20 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to "Supernus, Inc." The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.

Footnote F2

Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.

Footnote F3

These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in five installments. 40% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 15% of the RSUs vest upon the three-year anniversary of the Closing. 15% of the RSUs vest upon the four-year anniversary of the Closing.

Footnote F4

Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.

Footnote F5

On February 18, 2026, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on July 15, 2026.

Footnote F6

On February 19, 2025, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on May 3, 2025.

Footnote F7

On February 22, 2024, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on June 24, 2024.

Footnote F8

Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

Footnote F9

These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.

Footnote F10

These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.

Footnote F11

These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.

Footnote F12

These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.

Footnote F13

Option vests in four equal installments beginning February 22, 2020.

Footnote F14

The option vests in four equal annual installments beginning on February 21, 2021.

Footnote F15

The option vests in four equal annual installments beginning on February 19, 2022

Footnote F16

The option vests in four equal annual installments beginning on February 22, 2023.

Footnote F17

The option vests in four equal annual installments beginning on February 23, 2024.

Footnote F18

The option vests in four equal annual installments beginning on February 22, 2025.

Footnote F19

The option vests in four equal annual installments beginning on February 19, 2026.

Footnote F20

The option vests in four equal annual installments beginning on February 18, 2027.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .